# A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct06937203` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06937203](<https://clinicaltrials.gov/study/NCT06937203>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06937203

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 150 participants.

## Technical summary

Registry record NCT06937203. Randomized; quadruple masking; primary purpose treatment. Start 2025-05-09 (actual); primary completion 2027-02 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 1/2
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT06937203, source copy `cardio:ctgov-nct06937203-2026-07-08`, retrieved 2026-10-26)
- Started: 2025-05-09 (actual) (ClinicalTrials.gov record NCT06937203, source copy `cardio:ctgov-nct06937203-2026-07-08`, retrieved 2026-10-26)
- Primary completion: 2027-02 (anticipated) (ClinicalTrials.gov record NCT06937203, source copy `cardio:ctgov-nct06937203-2026-07-08`, retrieved 2026-10-26)
- Completion: 2027-02 (anticipated) (ClinicalTrials.gov record NCT06937203, source copy `cardio:ctgov-nct06937203-2026-07-08`, retrieved 2026-10-26)
- Countries: Australia; New Zealand (ClinicalTrials.gov record NCT06937203, source copy `cardio:ctgov-nct06937203-2026-07-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06937203-2026-07-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus
- Condition: Obesity
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): ARO-ALK7
- Intervention (Drug): Placebo
- Lead sponsor: Arrowhead Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Arrowhead Pharmaceuticals (`cardio:org-arrowhead-pharmaceuticals`)

## Provenance

Content hash: 1a2b747c415262f04bc7d91d757068fd89e0c2b19f239804e0959aff2436b080
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
